RenovoRx (RNXT)
NASDAQ:RNXT
US Market

RenovoRx (RNXT) Stock Price & Analysis

24 Followers

RNXT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.50 - $5.75
Previous Close$1.9
Volume13.77K
Average Volume (3M)51.42K
Market Cap
$19.25M
Enterprise Value$15.55M
Total Cash (Recent Filing)$3.70M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.7
Beta1.10
Aug 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding10,131,798
10 Day Avg. Volume20,050
30 Day Avg. Volume51,421
Standard Deviation0.28
R-Squared0.00002
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)5.91
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.22
Forecast
Price Target Upside383.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.

---

RNXT FAQ

What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $1.50 and its highest was $5.75 in the past 12 months.
    What is RenovoRx’s market cap?
    Currently, no data Available
    When is RenovoRx’s upcoming earnings report date?
    RenovoRx’s upcoming earnings report date is Aug 14, 2023 which is in 75 days.
      How were RenovoRx’s earnings last quarter?
      RenovoRx released its earnings results on May 15, 2023. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.215 by -$0.145.
        Is RenovoRx overvalued?
        According to Wall Street analysts RenovoRx’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does RenovoRx pay dividends?
          RenovoRx does not currently pay dividends.
          What is RenovoRx’s EPS estimate?
          RenovoRx’s EPS estimate is -$0.29.
            How many shares outstanding does RenovoRx have?
            RenovoRx has 10,131,798 shares outstanding.
              What happened to RenovoRx’s price movement after its last earnings report?
              RenovoRx reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.215. Following the earnings report the stock price went up 10.945%.
                Which hedge fund is a major shareholder of RenovoRx?
                Currently, no hedge funds are holding shares in RNXT

                ---

                RenovoRx Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                RenovoRx

                RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.

                ---

                Top 5 ETFs holding RNXT

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold RNXT. The ETFs are listed according to market value of RNXT within the ETF

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Cellectar Biosciences
                180 Life Sciences
                Humanigen
                Tempest Therapeutics
                Skye Bioscience

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis